**Documents for Knowledge Base**

Guidance:

Food and Drug Administration. *Framework for FDA’s Real-World Evidence Program*. US Food and Drug Administration Accessed August 31, 2022. https://www.fda.gov/media/120060/download

International Coalition of Medicines Regulatory Authorities. ICMRA statement on international collaboration to enable real-world evidence (RWE) for regulatory decision-making. In: ; 2022. Accessed October 3, 2024. https://icmra.info/drupal/sites/default/files/2022-07/icmra\_statement\_on\_rwe.pdf

Committee for Medicinial Products for Human Use. ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate real-world evidence, with a focus on effectiveness of medicines. Published online July 25, 2024. <https://ema.europa.eu/en/documents/scientific-guideline/ich-reflection-paper-pursuing-opportunities-harmonisation-using-real-world-data-generate-realworld-evidence-focus-effectiveness-medicines_en.pdf>

Food and Drug Administration. *Real‐world Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision‐making for Drug and Biological Products*. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Oncology Center of Excellence (OCE); 2024. Accessed August 17, 2024. <https://onlinelibrary.wiley.com/doi/10.1002/pds.5444>

Center for Drug Evaluation and Research. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products. July 25, 2024. Accessed October 2, 2024. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory>

Center for Drug Evaluation and Research. Data Standards for Drug and Biological Product Submissions Containing Real-World Data. December 22, 2023. Accessed October 2, 2024. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data>

CDRH. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. June 26, 2023. Accessed October 2, 2024. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices>

Center for Drug Evaluation and Research. Designing Sound Clinical Trials That Incorporate Real-World Data. *FDA*. Published online August 19, 2022. Accessed October 2, 2024. <https://www.fda.gov/drugs/regulatory-science-action/designing-sound-clinical-trials-incorporate-real-world-data>

Studies:

Pulini AA, Caetano GM, Clautiaux H, Vergeron L, Pitts PJ, Katz G. Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation. *Ther Innov Regul Sci*. 2021;55(1):228-238. doi:10.1007/s43441-020-00208-1

Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. *Clin Pharmacol Ther*. 2022;111(1):135-144. doi:10.1002/cpt.2474

Wallach JD, Zhang AD, Skydel JJ, et al. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. *JAMA Netw Open*. 2021;4(11):e2133667. doi:10.1001/jamanetworkopen.2021.33667

Mofid S, Bolislis WR, Kühler TC. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. *Clin Ther*. 2022;44(2):306-322. doi:10.1016/j.clinthera.2021.12.010

Tsafnat G, Dunscombe R, Gabriel D, Grieve G, Reich C. Converge or Collide? Making Sense of a Plethora of Open Data Standards in Health Care. *J Med Internet Res*. 2024;26:e55779. doi:10.2196/55779

Facile R, Muhlbradt EE, Gong M, et al. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey. *JMIR Med Inform*. 2022;10(1):e30363. doi:10.2196/30363

Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. *J Biomed Inform*. 2016;64:333-341. doi:10.1016/j.jbi.2016.10.016

Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative, et al. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. *JAMA*. 2023;329(16):1376-1385. doi:10.1001/jama.2023.4221

Lee S, Lee JH, Kim GJ, et al. A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation. *J Med Internet Res*. 2022;24(10):e35464. doi:10.2196/35464

Y D, EC P, JD W, et al. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. *BMJ (Clinical research ed)*. 2022;379:e070717. doi:10.1136/bmj-2022-070717

JJ Y, YH C, P R, J H, MA H, S HD. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. *Human reproduction (Oxford, England)*. 2022;37(4):793-805. doi:10.1093/humrep/deac005

Crown WH. Real-World Evidence, Causal Inference, and Machine Learning. *Value Health*. 2019;22(5):587-592. doi:10.1016/j.jval.2019.03.001

Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. *Rheumatology*. 2018;57(Supplement\_7):vii54-vii58. doi:10.1093/rheumatology/key109

Reviews:

Mackowiak JI, Mack CD, Irwin DE, Zura R. Randomized Clinical Trial or Real-World Evidence: How Historical Events, Public Demand, and the Resulting Laws and Regulations Shaped the Body of Medical Evidence. *J Orthop Trauma*. 2021;35(Suppl 1):S17-S21. doi:10.1097/BOT.0000000000002040

Vaghela S, Tanni KA, Banerjee G, Sikirica V. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases. *Orphanet Journal of Rare Diseases*. 2024;19(1):117. doi:10.1186/s13023-024-03111-2

Arondekar B, Duh MS, Bhak RH, et al. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. *Clin Cancer Res*. 2022;28(1):27-35. doi:10.1158/1078-0432.CCR-21-2639

Curtis LH, Sola-Morales O, Heidt J, et al. Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls. *Clin Pharmacol Ther*. 2023;114(2):303-315. doi:10.1002/cpt.2913

Wang CY, Berlin JA, Gertz B, et al. Uncontrolled Extensions of Clinical Trials and the Use of External Controls-Scoping Opportunities and Methods. *Clin Pharmacol Ther*. 2022;111(1):187-199. doi:10.1002/cpt.2346

Singh K, Concato J, Davis JM. Real-World Evidence for Neonatal Drug Development: Challenges and Opportunities. *The Journal of Pediatrics*. 2024;265:113806. doi:10.1016/j.jpeds.2023.113806

Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions - Sola‐Morales - 2023 - Clinical Pharmacology & Therapeutics - Wiley Online Library. Accessed October 2, 2024. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.2914

Djurisic S, Rath A, Gaber S, et al. Barriers to the conduct of randomised clinical trials within all disease areas. *Trials*. 2017;18(1):360. doi:10.1186/s13063-017-2099-9

Milner S, Kusmierczyk AR, Taccoen J. The unique challenges of clinical trials in rare disease: A regulatory writer’s perspective. *MEW*. 2023;32:54-57.

Mellerio JE. The challenges of clinical trials in rare diseases. *British Journal of Dermatology*. 2022;187(4):453-454. doi:10.1111/bjd.21686

Opinion:

Concato J, Corrigan-Curay J. Real-World Evidence — Where Are We Now? *New England Journal of Medicine*. 2022;386(18):1680-1682. doi:10.1056/NEJMp2200089

Greenbaum D. Making Compassionate Use More Useful: Using real-world data, real-world evidence and digital twins to supplement or supplant randomized controlled trials. *Pac Symp Biocomput*. 2021;26:38-49.

Wallach JD, Ross JS, Naci H. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. *Clin Trials*. 2018;15(3):219-229. doi:10.1177/1740774518770648

Heavner SF, Anderson W, Kashyap R, et al. A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools. *Crit Care Explor*. 2023;5(4):e0893. doi:10.1097/CCE.0000000000000893

Zhu R, Vora B, Menon S, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective. *Clin Pharmacol Ther*. 2023;114(4):751-767. doi:10.1002/cpt.2988